Open AccessSemaphorin 3A (SEMA3A), protocadherin 9 (PCdh9), and S100 calcium binding protein A3 (S100A3) as potential biomarkers of carcinogenesis and chemoresistance of different neoplasms, including ovarian cancer — review of literature
Author(s) -
Natalia Iżycka,
Karolina Sterzyńska,
Radosław Januchowski,
Ewa NowakMarkwitz
Publication year - 2019
Publication title -
ginekologia polska
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.4
H-Index - 21
eISSN - 2543-6767
pISSN - 0017-0011
DOI - 10.5603/gp.2019.0040
Subject(s) - carcinogenesis , protocadherin , ovarian cancer , cancer research , medicine , semaphorin , cancer , drug resistance , cancer cell , cytotoxic t cell , bioinformatics , biology , cell , in vitro , cadherin , genetics , receptor
Ovarian cancer is the fifth leading cause of cancer-related deaths in women. Its high mortality rate results from lack of adequate and sensitive methods allowing for the detection of the early stages of the disease, as well as low efficiency of the treatment, caused by the cytotoxic drug resistance of cancer cells. Unfortunately, tumours are able to develop new pathways and protective mechanisms that allow them to survive toxic conditions of chemotherapy. Therefore, intensive search for new genes and proteins involved in resistance to cytotoxic drugs is still needed, especially from a clinical point of view. The article presents an overview of the available literature on the role of semaphorin 3A (SEMA3A), protocadherin 9 (PCDH9), and S100 calcium binding protein A3 (S100A3) in carcinogenesis and chemoresistance of various tumors including ovarian cancer. As it turns out, the role of described genes/proteins is not limited only to their native biological activity but they function also as an oncogenic or suppressor factors in the tumor development. Moreover, they can also play an important role in development of drug resistance, as it was shown in ovarian cancer cell lines.